What are the Cardiovascular Benefits of GLP-1 Medication?
GLP-1 receptor agonists entered the national conversation as a breakthrough in weight loss and weight management.
Now, researchers and clinicians are increasingly recognizing that these medications may offer powerful benefits for the heart and cardiovascular system.
Here’s what the emerging science says, and why it matters for anyone managing their long-term health.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a hormone naturally produced in the gut.
Originally developed to treat type 2 diabetes, GLP-1 medications like Semaglutide and Tirzepatide have become widely used for weight loss.
They work by stimulating insulin release, suppressing glucagon, slowing stomach emptying, and reducing appetite.
This multi-pronged mechanism produces meaningful weight loss in many patients. But as these medications are studied, science is revealing other potential benefits.
How Might GLP-1 Medications Protect the Heart?
Researchers are still working to fully understand the specifics, but several pathways appear to be at play.
GLP-1 Impact on Inflammation
Inflammation is a contributor to many conditions, including plaque buildup in the arteries (the major cause of heart attack and stroke).
In studies, GLP-1s show promise in reducing inflammatory markers like C-reactive protein (CRP).
GLP-1 Impact on Blood Pressure
High blood pressure damages the cardiovascular system over time by forcing the heart to work harder.
GLP-1 medications show consistent, small improvements in systolic blood pressure (the top number in a reading).
GLP-1s and Lipid Balance
Lipids include triglycerides (most common type of fat in the body), LDL cholesterol (known as bad cholesterol) and HDL cholesterol (known as good cholesterol). High triglycerides and LDL cholesterol can lead to arterial wall thickening and plaque buildup.
In studies, GLP-1 shows effectiveness in lowering triglycerides and LDL cholesterol levels, plus improving HDL cholesterol.
GLP-1s Reduce Visceral Fat
Visceral fat is belly fat that gathers around vital organs. It can lead to inflammation, insulin resistance and type 2 diabetes, heart disease, and more.
GLP-1 medications are particularly effective at reducing visceral fat by reducing appetite, encouraging lifestyle changes, and improving metabolic health.
GLP-1 Impact on Cardiac Tissue
GLP-1 medication may protect the health of cardiac tissue itself.
Cardiac tissue is specialized muscle that makes up the middle of the heart wall. GLP-1s may decrease cell death in cardiac tissue and reduce inflammation. This can lead to positive cardiovascular outcomes.
GLP-1s May Reduce Atrial Fibrillation Risk
GLP-1 medication may reduce the risk of developing an atrial fibrillation (AF), which is a heart arrhythmia that leads to rapid and irregular heartbeats. Over time, AF can damage the heart and lead to heart failure if left untreated.
A recent data analysis found that patients on a GLP-1 medication who received an ablation treatment for AF were significantly less likely to experience a reoccurring AF within 2 years.
GLP-1 Medication and Heart Failure
A 2023 study tested the impact of Semaglutide on patients with heart failure with preserved ejection fraction (HFpEF) and obesity. There are few treatments available for this type of patient, and HFpEF is historically difficult to treat.
Study participants on Semaglutide reported significant improvements in symptoms, physical limitations, and exercise capacity compared to the placebo group. They also saw greater weight loss.
A 2024 study of the same population utilizing Tirzepatide found similar results, with participants experiencing improved health and reduced risk of fatal cardiovascular events.
GLP-1 Cardiovascular Studies
There are several studies that point to the cardiovascular benefits of GLP-1 medication.
One 2016 study looked into the use of liraglutide in patients with type 2 diabetes and established cardiovascular disease. Patients taking liraglutide saw a 13% reduction in major cardiovascular events compared to the group that didn’t receive a GLP-1.
Another 2016 study focused on Semaglutide in patients with type 2 diabetes, many of whom also had cardiovascular disease, kidney disease, or both. The study found that major cardiovascular events were significantly reduced in the group receiving Semaglutide compared to the placebo group.
A Landmark Study in 2023
A more recent 2023 study had major findings related to GLP-1s and cardiovascular disease. This was the first large-scale study to focus on obese patients with cardiovascular disease who did not have type 2 diabetes. The study found that a 2.4mg dose of Semaglutide reduced the risk of death via major cardiovascular events by up to 20% compared to the control group.
These results strongly suggest that GLP-1 medications have cardiovascular benefits beyond glucose control and weight loss.
FDA Approves Semaglutide to Reduce Cardiac Events
The landmark 2023 study led to the FDA approving Semaglutide (under the brand name Wegovy®) for reducing the risk of cardiovascular death, heart attack, and stroke.
The approval applies to adults with cardiovascular disease who are obese or overweight.
Are the Cardiovascular Benefits Caused by Weight Loss?
GLP-1 medication is known for triggering significant weight loss. When evaluating the cardiovascular benefits of GLP-1s, an important question is whether benefits come from weight loss.
Losing weight does typically improve cardiovascular health, leading to better lipid balance, reduced blood pressure, less inflammation, and reduced comorbidities.
However, the 2023 study on Semaglutide (called the SELECT study) shows promising evidence that GLP-1 medication has cardiovascular benefits beyond weight loss.
There are GLP-1 receptors in the heart, blood vessels, kidneys, and brain, and these receptors may be the reason GLP-1s offer such benefits.
What This Means for Patients Considering GLP-1 Therapy
The emerging cardiovascular benefits of GLP-1s expand the potential uses for this revolutionary medication.
While mostly considered weight loss medications, GLP-1s like Semaglutide also show significant benefit in reducing the risk of heart attack, stroke, and cardiovascular death in high-risk patients. Emerging evidence also points to potential benefits like lowered inflammation, protection of heart tissue, reduced chance of developing atrial fibrillation, and more.
If you’ve been curious about GLP-1 therapy primarily for weight management, it’s worth discussing your full cardiovascular risk profile with your provider, as well.
At Defy Medical, our providers take an individualized, evidence-based approach to weight loss and metabolic health. They consider your complete health picture before recommending a customized protocol.
Ready to see if GLP-1 therapy is right for you?
Get StartedRelated Health Articles
LIPO-C Injections Patient Handout
LIPO-C is a lipotropic injections that may encourage fat-burning, boost energy, preserve lean muscle, and more.
Learn More About LIPO-C Injections Patient Handout
How to Break a Weight Loss Plateau
Weight loss plateaus are inevitable when you're trying to lose pounds. There are ways to identify and break a weight loss plateau.
Learn More About How to Break a Weight Loss Plateau
FDA Approves Semaglutide to Reduce Cardiovascular Events
The FDA approved an additional indication for Semaglutide: to lower the risk of death via cardiac events in overweight and obese patients.
Learn More About FDA Approves Semaglutide to Reduce Cardiovascular Events